FDA approves daraxonrasib (RASONQUE) for metastatic pancreatic adenocarcinoma

On 26 August 2026 the US Food and Drug Administration (FDA) approved daraxonrasib, marketed as RASONQUE by Revolution Medicines, for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi‑agent chemotherapy. The announcement, published by the FDA, cites a randomized Phase‑3 clinical trial as the pivotal evidence.

The approval covers a population of patients with advanced disease for whom therapeutic options are limited. The FDA emphasizes that the approval is for an indication in previously treated patients and does not describe daraxonrasib as curative. Revolution Medicines issued a concurrent press release confirming the FDA decision, and the development was covered by independent outlets including the Associated Press.

The FDA based its decision primarily on the RASolute‑302 Phase‑3 study (NCT06625320), a randomized, open‑label, multicenter trial that enrolled 500 patients who were randomized 1:1 to receive daraxonrasib or investigator‑chosen standard chemotherapy. According to the FDA, median overall survival (OS) across the trial population was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy, corresponding to a hazard ratio of 0.40 (p < 0.0001).

Progression‑free survival (PFS) was also longer with daraxonrasib, 7.2 months versus 3.6 months. The magnitude and statistical significance of these differences were judged by the agency to represent a clinically meaningful benefit in this patient population. The study’s open‑label design and ongoing follow‑up for long‑term outcomes were noted as considerations in the overall assessment.

Daraxonrasib is an orally administered tablet intended for once‑daily dosing; the FDA lists the recommended dose as 300 mg taken orally once per day. The active molecule is described as a RAS(ON) multiselective inhibitor that targets active forms of RAS including KRAS, intervening in a signaling pathway central to many pancreatic tumors. An oral targeted agent marks a different therapeutic approach compared with many traditional cytotoxic regimens.

As with most novel oncology drugs, the approval is accompanied by a detailed safety profile. Common adverse reactions reported in the trial and highlighted by the FDA include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, peripheral edema, decreased appetite, and bleeding. The agency also lists warnings about dermatologic/soft tissue events, gastrointestinal perforation, interstitial lung disease/pneumonitis, and embryo‑fetal toxicity. Clinicians will need to balance the survival benefit against these known risks and to monitor patients accordingly.

The drug’s pathway to approval involved several expedited regulatory designations: daraxonrasib received Breakthrough Therapy and Orphan Drug designations, as well as Priority Review. The FDA reviewed the application under Project Orbis, an international collaboration that facilitates concurrent review by participating regulatory authorities; Health Canada participated, while the European Medicines Agency (EMA) and Japan’s PMDA served as observers. Project Orbis can accelerate decision‑making across jurisdictions, but it does not itself confer approvals outside the participating country.

At the time of the FDA announcement, Revolution Medicines had not disclosed a US launch date, supply timelines, pricing or reimbursement plans. Similarly, there is no automatic European authorization: EMA involvement as an observer means European regulators are informed but must conduct their own assessments. Whether and when daraxonrasib will receive approval in the EU, the UK, Japan or elsewhere remains contingent on local regulatory submissions and reviews.

The FDA decision represents a clinically important development in a malignancy long characterized by limited therapeutic advances. The RASolute‑302 results show a substantial median survival improvement—nearly doubling OS in the trial population—which could translate into meaningful benefit for patients whose disease has progressed after prior therapy. However, it is equally important to underline that this is not a cure: the approval is based on prolongation of median survival and improved PFS, not eradication of disease.

Key practical issues are not yet resolved. The FDA document does not address price, insurance coverage, or immediate availability in the US market; Revolution Medicines’ statement confirmed approval but gave no commercial timeline. Health systems and oncologists will need data on longer‑term outcomes, subgroup responses by prior therapy, and real‑world tolerability to integrate the drug into practice. Ongoing monitoring for the serious adverse events noted by the agency will be essential.

Moreover, the broader regulatory and access picture is incomplete. International decisions will depend on separate submissions and reviews; Project Orbis speeds information exchange but does not guarantee synchronised approvals. From a scientific perspective, independent analyses and peer‑reviewed publications (the FDA notes conference presentations and journal reports) will be scrutinized to assess reproducibility and to guide guideline updates. Until those processes and commercial arrangements are clarified, the immediate impact will be limited to patients in the United States who can access daraxonrasib under approved pathways and to broader scientific and health‑policy discussions about how to deploy this new targeted option.